Clovis Sets Brisk Development Timetable For Lung Cancer Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The oncology drug developer expects to file its third generation EGFR inhibitor for the treatment of NSCLC by the end of 2015, CEO Patrick Mahaffy told investors during an R&D day Jan. 27. Investors are enthusiastic about the potential of the drug, which could address a sizeable commercial market.
You may also be interested in...
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.
Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.
What Seagen’s Pipeline Will Bring To Pfizer
Seagen’s pipeline includes 11 new molecular entities and would double Pfizer’s early-stage oncology clinical pipeline. A next-generation cytotoxic payload for ADCs is on the way too.